Octan glatirameru (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Octan glatirameru" in Polish language version.

refsWebsite

Global rank Polish rank

2^nd place

6^th place

4^th place

7^th place

low place

1,102^nd place

low place

low place

1^st place

8,738^th place

165^th place

doi.org

D.D. Teitelbaum D.D. i inni, Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, „European Journal of Immunology”, 1 (4), 1971, s. 242–248, DOI: 10.1002/eji.1830010406, PMID: 5157960 [dostęp 2021-02-09] (ang.).
M.B.M.B. Bornstein M.B.M.B. i inni, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, „The New England Journal of Medicine”, 317 (7), 1987, s. 408–414, DOI: 10.1056/NEJM198708133170703, PMID: 3302705 [dostęp 2021-02-09] (ang.).
K.P.K.P. Johnson K.P.K.P. i inni, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, „Neurology”, 45 (7), 1995, s. 1268–1276, DOI: 10.1212/wnl.45.7.1268, PMID: 7617181 [dostęp 2021-02-09] (ang.).
G.G. Comi G.G., M.M. Filippi M.M., J.S.J.S. Wolinsky J.S.J.S., European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, „Annals of Neurology”, 49 (3), 2001, s. 290–297, DOI: 10.1002/ana.64, PMID: 11261502 [dostęp 2021-02-09] (ang.).

Glatiramer (octan glatirameru), [w:] Indeks Leków MP, opis substancji, Medycyna Praktyczna [dostęp 2021-02-09] .

IwonaI. Rościszewska-Żukowska IwonaI., MirosławM. Dziki MirosławM., HalinaH. Bartosik-Psujek HalinaH., Leki immunomodulacyjne a ciąża w stwardnieniu rozsianym, „Polski Przegląd Neurologiczny”, 12 (3), 2016, s. 146–156 [dostęp 2021-02-09] .

D.D. Teitelbaum D.D. i inni, Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, „European Journal of Immunology”, 1 (4), 1971, s. 242–248, DOI: 10.1002/eji.1830010406, PMID: 5157960 [dostęp 2021-02-09] (ang.).
M.B.M.B. Bornstein M.B.M.B. i inni, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, „The New England Journal of Medicine”, 317 (7), 1987, s. 408–414, DOI: 10.1056/NEJM198708133170703, PMID: 3302705 [dostęp 2021-02-09] (ang.).
K.P.K.P. Johnson K.P.K.P. i inni, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, „Neurology”, 45 (7), 1995, s. 1268–1276, DOI: 10.1212/wnl.45.7.1268, PMID: 7617181 [dostęp 2021-02-09] (ang.).
G.G. Comi G.G., M.M. Filippi M.M., J.S.J.S. Wolinsky J.S.J.S., European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, „Annals of Neurology”, 49 (3), 2001, s. 290–297, DOI: 10.1002/ana.64, PMID: 11261502 [dostęp 2021-02-09] (ang.).

RuthR. Arnon RuthR., MichaelM. Sela MichaelM., The chemistry of the Copaxone drug, „Chem. Isr.”, 1, 1999, s. 12–17 (ang.).